GE HealthCare stock (US36266G1076): Leader in precision health imaging

GE HealthCare continues to drive innovation in medical imaging and diagnostics, serving US hospitals with advanced AI-enabled technologies amid growing demand for precision medicine.

GE HealthCare, a global leader in medical technology, maintains its focus on precision health solutions including imaging systems, ultrasound, and patient monitoring. The company, spun off from General Electric in 2023, reported steady performance in its latest quarterly results for Q4 2025 published on February 13, 2026, showing revenue of $5.3 billion, up 2% year-over-year, driven by strong demand in the US market, according to GE HealthCare press release as of 02/13/2026.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: GE HealthCare Technologies Inc.
• Sector/industry: Health Care Equipment & Supplies
• Headquarters/country: Chicago, United States
• Core markets: North America, Europe, Asia
• Key revenue drivers: Imaging systems, ultrasound, pharmaceuticals
• Home exchange/listing venue: Nasdaq (GEHC)
• Trading currency: USD

GE HealthCare: core business model

GE HealthCare develops and manufactures advanced medical products and digital solutions for hospitals and clinics worldwide. Its portfolio spans four main segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. Imaging, the largest segment, includes MRI, CT scanners, and X-ray systems enhanced with AI for faster diagnostics. The company invests heavily in software integration to improve workflow efficiency in US healthcare facilities facing staffing shortages.

In the US, GE HealthCare holds a significant market share in precision imaging, benefiting from the expansion of Medicare-covered advanced diagnostics. For the full year 2025, Imaging revenue reached $7.8 billion, representing about 45% of total sales, as reported in the annual filing published February 13, 2026, according to SEC 10-K as of 02/13/2026.

Main revenue and product drivers for GE HealthCare

Key products like the Revolution Apex CT scanner and SIGNA MRI systems drive growth, with AI features reducing scan times by up to 30%. Ultrasound remains a steady performer, generating $2.1 billion in 2025 revenue, fueled by portable devices popular in US outpatient settings. Pharmaceutical Diagnostics, including contrast agents, supports imaging procedures and posted 1% organic growth in Q4 2025.

US investors note GE HealthCare's exposure to the $500 billion US medical imaging market, projected to grow 6% annually through 2030 per MarketsandMarkets report as of 01/2026. Recent product launches, such as the Vscan Air SL wireless ultrasound in late 2025, target point-of-care diagnostics in American emergency rooms.

Industry trends and competitive position

The medical imaging sector is shifting toward AI integration and sustainability, areas where GE HealthCare excels. Competitors like Siemens Healthineers and Philips compete fiercely, but GE's installed base of over 5 million devices worldwide provides service revenue stability. In the US, its partnerships with major hospital chains enhance market penetration.

Sustainability efforts include low-dose imaging protocols reducing radiation exposure, aligning with regulatory pushes from the FDA. GE HealthCare's R&D spend of $1.3 billion in 2025, or 7% of revenue, supports a pipeline of 20+ innovations, positioning it well in the precision medicine era.

Why GE HealthCare matters for US investors

Listed on Nasdaq as GEHC, GE HealthCare offers US investors direct exposure to healthcare innovation amid aging demographics and rising procedure volumes. The US accounts for 45% of its revenue, tying performance to domestic healthcare spending, which hit $4.5 trillion in 2025 per CMS data.

Its focus on AI diagnostics addresses labor shortages in US radiology departments, where demand for scans outpaces workforce growth. Dividend payments of $0.14 per share quarterly provide yield, appealing to income-focused portfolios tracking the S&P 500 Health Care Index.

Conclusion

GE HealthCare sustains its role as a key player in medical technology, with robust US market presence and innovation in AI-driven diagnostics. Recent financials indicate resilience amid sector growth, while ongoing R&D investments signal long-term potential. Investors monitor upcoming Q1 2026 results expected in late April for further insights into performance.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.